Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...
Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 100 Technology Square Cambridge, Massachusetts 02139 |
| Phone | +1.857.242.0170 |
| Number of Employees | N/A |
| Recent SEC Filing | 01/10/2022 8-K |
| President, Chief Executive Officer & Director | Jason Gardner |
| COO, CFO, Treasurer & Chief Accounting Officer | Stephen Frank Mahoney |
| Chief Scientific Officer & Head-Research | Lisa M. Olson |
| Chief Technical Officer | David Nichols |
| Price Open | $3.72 |
| Previous Close | $3.71 |
| 52 Week Range | $3.47 - 14.20 |
| Market Capitalization | $209.5 M |
| Shares Outstanding | 58.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.35 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -42.08% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
